Status:
COMPLETED
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Wegener's Granulomatosis
Churg-Strauss Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
Detailed Description
The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Str...
Eligibility Criteria
Inclusion
- Systemic ANCA positive (+) vasculitides
- Relapsing or refractory vasculitides, resistant to corticosteroids and reference immunosuppressant therapies
- Age \>18 years old
- Written informed consent
Exclusion
- Newly diagnosed patient
- Patient that had never received an immunosuppressant before to treat his/her vasculitis
- Malignancy
- Pregnancy
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00307593
Start Date
May 1 2004
End Date
June 1 2007
Last Update
November 19 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Cochin
Paris, France, 75679